Imugene Limited
Sydney, AU· latest recorded location
Imugene Limited is named on 2 US grants and 4 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 2
- Published applications
- 4
- Inventors
- 11
- Granted in 2026 so far
- 1
- Most recent grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 1 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 6 documents
Recent patents
- Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers4 Aug 2026US 12,698,512 B2
- Vaccine composition and uses thereof27 May 2025US 12,311,019 B2
- Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers8 May 2025US 2025/0146017 A1
- Vaccine composition and uses thereof5 Aug 2021US 2021/0236614 A1
- Porcine Adenovirus 3-Based PRRSV Vaccines1 Dec 2011US 2011/0293655 A1
- Methods and Compositions for Increasing Tissue Tropism of Recombinant Adenoviral Vectors29 Apr 2010US 2010/0104600 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.